Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1, MULTICENTER, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE

NCT06995729 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06995729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06995729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1, MULTICENTER, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Recruiting
Start date
May 16, 2025
Completion date
August 12, 2027
Enrollment
16 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

acute treatment of migraine